ProShares Ultra Nasdaq Biotechnology BIB
116.13 USD -1.47 (-1.25%)
Regular-session close
116.39 +0.26 +0.23%
After hours · Nov 13, 4:00 PM ET
114.30 Day range 116.60
73.81 52-week range 126.22
- YTD
- +45.56%
- 1 year
- +55.94%
News
defenseworld.net ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Shares Scheduled to Split on Thursday, November 19th Shares of ProShares Ultra Nasdaq Biotechnology (NASDAQ: BIB) are scheduled to split on the morning of Thursday, November 19th. The 2-1 split was recently announced. The newly created shares will be…
businesswire.com ProShares Announces ETF Share Splits BETHESDA, Md.--(BUSINESS WIRE)--ProShares announces forward and reverse share splits on 15 of its ETFs. The splits will not change the total value of a shareholder's investment.
defenseworld.net Capital Investment Advisors LLC Acquires New Holdings in ProShares Ultra Nasdaq Biotechnology $BIB Capital Investment Advisors LLC acquired a new position in shares of ProShares Ultra Nasdaq Biotechnology (NASDAQ: BIB) in the undefined quarter, according to its most recent 13F filing with the…
defenseworld.net ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Price Cross Below 50 Day Moving Average – What’s Next? ProShares Ultra Nasdaq Biotechnology (NASDAQ: BIB - Get Free Report)'s stock price crossed below its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $84.02…
defenseworld.net ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Shares Cross Above 50 Day Moving Average – Here’s Why ProShares Ultra Nasdaq Biotechnology (NASDAQ: BIB - Get Free Report)'s stock price crossed above its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $74.59…
seekingalpha.com BIB: A Tactical 2 X Leveraged Biotech ETF BIB seeks 2× the daily return of the Nasdaq Biotechnology Index, amplifying both gains and losses through leverage. A higher expense ratio reflects leverage costs and management fees; 24 bps…
investorplace.com Wall Street's Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich Some of the market's favorite biotech stocks have created immense wealth, as in the recent weight-loss drug stock boom. On May 26, Viking Therapeutics (NASDAQ: VKTX ) was trading around $20.25.
investorplace.com 3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024 With new innovation, high demand for better treatment, pharmaceutical companies strengthening pipelines and a resurgence of mergers and acquisitions, biotech stocks could offer some of the most…
seekingalpha.com Equity CEFs/ETFs: Top Picks For 2024 - Part II In Part I of my Top Picks For 2024, I explained why we saw such extreme valuation losses in most equity CEFs in 2023 and what that could-mean for 2024. In my opinion, liquidity was the over-riding…
benzinga.com Man in Germany Cured of HIV After Undergoing Stem Cell Transplant, According to Report in Nature Medicine https://www.dailymail.co.uk/health/article-11772327/Man-CURED-HIV-D-sseldorf-patient-virus-free.html?ito=social-twitter_mailonline https://www.nature.com/articles/s41591-023-02213-x
investorplace.com The 7 Best ETFs to Buy to Cover 2023's Biggest Investing Opportunities These are some of the best ETFs to buy and hold heading into New Year 2023. Rather than being completely tied to the ebb and flow of single-stock ideas, you can gain access to a broad number of…
investorplace.com The 7 Hottest Biotech Stocks to Own in 2023 and Beyond Some of the hottest biotech stocks are safe and recession-proof. After all, we can't stop people from aging – at least, not yet.
seekingalpha.com Why Now Could Be The Time To Consider Neuroscience Investments Recognition that aging populations will give rise to new healthcare needs and heightened awareness of mental health issues are bringing renewed focus to neurological health. Recent advances in…
etftrends.com Top Performing Leveraged/Inverse ETFs: 08/07/2022 Top Performing Levered/Inverse ETFs Last Week These were last week's top-performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
etftrends.com Cap-Weighting Crucial When Indexing Biotech The biotechnology industry is a bifurcated space. In one corner, you have nascent, small-cap companies that don't yet have steady revenue streams because their new drug or treatment is still in…
benzinga.com Psychedelics Company COMPASS Pathways To Join NASDAQ Biotechnology Index Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ: CMPS) revealed Friday that it has been selected for addition to the Nasdaq Biotechnology Index (NASDAQ: NBI), effective as…
etftrends.com How to Invest in Biotech in 2022 It's been a hard year for a lot of the biotech industry, with many hedge funds ending the year with significant losses, but there have been a number of shining stars that are expected to continue to…
zacks.com Take a Look at the Top-Performing Biotech ETFs YTD The pandemic has triggered a race to introduce vaccines and treatment options, opening up investment opportunities in the biotech sector.
zacks.com Tap the Red Hot Biotech Sector With These 2 Leveraged ETFs Investors could easily tap the bullish trend by considering a near-term long on the biotech sector.
etftrends.com Pfizer-BioNTech COVID-19 Vaccine Garners Full FDA Approval The FDA has officially given full approval to Pfizer and BioNTech for their COVID-19 vaccine, potentially making way for more approvals and more vaccine mandates, reports CNBC. It is a move that…
etftrends.com As Covid Cases Mutate, the Biotech Industry Works to Keep Up As the Delta variant sweeps across the globe, pharmaceutical and biotech companies are working to ensure vaccines continue to cover the population, as well as working on booster doses that can adapt…
zacks.com 5 Best Leveraged ETFs of Last Week We highlight a few leveraged ETF areas that won last week.- benzinga.com Exclusive: SunTrust Managing Director Discusses Bluebird Bio, A Leader In Gene Therapy
- benzinga.com Biotechs Are Ripping Following IPAB Ruling
benzinga.com New Study Suggests Drug Prices Have Doubled Since 2011: What's It Mean For The Market? 
benzinga.com ProShares Releases 2 New Leveraged Biotech ETFs 
benzinga.com Why Investors Should Closely Watch Celgene - benzinga.com UCB Sales Rise in Q1 - Analyst Blog
- benzinga.com Seven ETFs On A Roll (BIB, SOCL, TAN)
- benzinga.com If Stocks Keep Soaring, Get to Know These Leveraged ETFs
benzinga.com ProShares to Split 2, Reverse Split 9 ETFs - benzinga.com Low Volume, High Returns for These ETFs (BIB, FHC, DRW)
- benzinga.com Nine ETFs on a Roll (DRN, TQQQ, BIB, BGU)